Novo Nordisk's Anti-Inflammatory Heart Drug Fails Phase 3 Trial Despite Lowering Biomarkers

Novo Nordisk’s highly anticipated Phase 3 ZEUS clinical trial has missed its primary endpoint, failing to reduce the rate of serious cardiovascular events in high-risk patients. The results, presented Saturday, November 7, 2026, at the American Heart Association scientific sessions, deliver a significant setback to the inflammation hypothesis of heart disease.[1][2]

Researchers tested ziltivekimab, a monoclonal antibody designed to inhibit the inflammatory molecule interleukin-6. The global study enrolled approximately 6,200 patients who already suffered from atherosclerotic cardiovascular disease and concurrent chronic kidney disease, a population with exceptionally high mortality risk.[2][3]

While the drug successfully suppressed systemic inflammation by lowering IL-6 levels in the bloodstream, that biochemical victory did not translate into fewer heart attacks or strokes. The disconnect between the biomarker response and actual patient outcomes has left cardiologists reevaluating their models.[3][5]

Paul Ridker, the Mass General Brigham researcher who led the global trial, acknowledged the complexity of the findings. The results indicate that the pathway from systemic inflammation to acute cardiovascular events is far less straightforward than previously modeled by the industry.[5]

"These results, the fact that they're negative, does not invalidate that inflammation plays a very important role in cardiovascular disease," researchers noted following the presentation. However, the failure forces the medical community to question how best to target that inflammation therapeutically.[4]

The biomarker disconnect

For years, cardiovascular research has relied heavily on surrogate endpoints—measurable biomarkers that reliably predict clinical outcomes. The ZEUS trial was built on the premise that driving down IL-6 would directly reduce the plaque ruptures that cause acute cardiac events.[1][2]

Ziltivekimab performed exactly as engineered on a molecular level, clearing the targeted inflammatory proteins from circulation. Yet the patients receiving the monthly injections experienced major adverse cardiovascular events at rates statistically indistinguishable from those receiving a placebo over the follow-up period.[3][6]

This outcome mirrors another high-profile disappointment revealed at the same 2026 conference. Novartis reported that its experimental drug pelacarsen successfully lowered lipoprotein(a)—a known genetic risk factor for heart disease—but also failed to prevent cardiovascular events in its own Phase 3 trial.[1]

The dual failures of ziltivekimab and pelacarsen highlight a growing crisis in cardiovascular drug development. Altering a blood test result is no longer a guaranteed proxy for extending a patient's life or preventing a stroke, complicating future regulatory submissions.[1][3]

The patient population selected for the ZEUS trial represents one of the most vulnerable cohorts in modern cardiology. Individuals battling both atherosclerotic cardiovascular disease and chronic kidney disease face mortality rates approaching 20 percent over a standard five-year period.[2][3]

Reassessing the inflammation theory

The inflammation hypothesis gained massive traction following the 2017 CANTOS trial, which evaluated over 10,000 patients and showed that targeting a different inflammatory pathway could modestly reduce cardiovascular risk. That earlier success drove billions of dollars into developing next-generation anti-inflammatory agents.[5]

Interleukin-6 sits further downstream in the inflammatory cascade than the targets of previous successful interventions. Researchers hypothesized that blocking this specific molecule would provide a more precise, potent intervention without compromising the broader immune system of vulnerable patients.[2][5]

The neutral findings from ZEUS suggest that blocking IL-6 alone is insufficient to halt the progression of atherosclerotic plaques in patients with advanced disease. The inflammatory network may simply bypass the blocked pathway using alternative molecular routes to sustain the damage.[3][5]

"Like cholesterol, inflammation causally contributes to the risk of cardiovascular disease," the Mass General Brigham research team emphasized in their trial breakdown. The challenge now lies in identifying which specific inflammatory pathways drive plaque instability before a rupture occurs.[5]

Cardiologists attending the November 2026 sessions expressed frustration but maintained that the underlying biological theory remains sound. The clinical focus must now shift toward earlier intervention or combination therapies that address multiple inflammatory pathways simultaneously to achieve a clinical benefit.[4][5]

Pipeline implications for Novo Nordisk

For Novo Nordisk, the ZEUS trial represented a strategic effort to diversify its cardiovascular portfolio beyond its blockbuster GLP-1 receptor agonists. The company acquired the rights to ziltivekimab in a $725 million acquisition specifically to target patients who might not benefit from weight-loss therapies.[1]

The failure leaves a significant gap in the pharmaceutical giant's late-stage pipeline for chronic kidney disease complications. Investors had closely monitored the Phase 3 program, anticipating a new standard of care for a notoriously difficult-to-treat population that currently lacks targeted options.[1][3]

The results also raise immediate questions about the ongoing HERMES trial, a parallel Phase 3 study evaluating approximately 5,600 patients with heart failure and preserved ejection fraction. That trial shares the same fundamental mechanism of action and relies on the identical IL-6 inhibition strategy.[1][2]

If the biomarker disconnect observed in ZEUS holds true across other cardiovascular conditions, the entire clinical development program for ziltivekimab could be in jeopardy. Novo Nordisk has not yet announced any modifications or early halts to its remaining cardiovascular trials.[1][6]

The broader pharmaceutical industry is now forced to recalibrate its risk models for cardiovascular investments. Trials requiring tens of thousands of patients and hundreds of millions of dollars face a higher evidentiary bar when surrogate markers prove unreliable predictors of success.[1][3]

Regulatory and competitive fallout

The failure of ziltivekimab also impacts the competitive landscape among major drugmakers racing to dominate the cardiovascular space. Companies developing alternative anti-inflammatory agents must now prove their compounds do more than simply suppress circulating biomarkers to justify their premium pricing.[1][3]

Analysts suggest the ZEUS data will prompt the Food and Drug Administration to scrutinize future trial designs more closely. Regulators may demand longer follow-up periods and larger patient cohorts to ensure that biochemical improvements genuinely translate into reduced mortality rates.[1][6]

The medical community must now digest the massive dataset generated by the global trial to identify any subgroups that might have benefited. Post-hoc analyses often reveal specific patient profiles that respond differently to the intervention, though these rarely support immediate regulatory approval.[3][5]

Researchers will specifically look at whether patients with the highest baseline levels of systemic inflammation showed any divergence in cardiovascular outcomes. However, regulatory agencies demand prospective trials to confirm any signals found during these retrospective data dives.[2][5]

AI

The path forward for patients

For patients living with concurrent heart and kidney disease, the ZEUS results mean waiting longer for targeted therapies. Current treatment protocols will continue to rely heavily on managing blood pressure, controlling lipids, and utilizing existing metabolic drugs to mitigate risk.[2][3]

The American College of Cardiology noted that the trial's rigorous design provides invaluable data on the natural progression of cardiovascular disease in patients with chronic kidney disease. This baseline data will inform the design and powering of future clinical trials in this space.[2]

Some researchers argue that the timing of the intervention plays a critical role in the drug's efficacy. Administering an IL-6 inhibitor to patients who already have advanced atherosclerotic plaques may simply be intervening too late in the disease process to prevent a rupture.[2][5]

Future trials may need to target younger patients with early-stage systemic inflammation before irreversible vascular damage occurs. However, running decades-long prevention trials in healthier populations presents massive logistical and financial hurdles for pharmaceutical companies seeking a return on investment.[3][4]

The dual setbacks at the 2026 conference serve as a stark reminder of the biological complexity of the human cardiovascular system. Fixing a single broken pathway is rarely enough to reverse decades of systemic metabolic dysfunction and established vascular disease.[1][4]

The next major breakthrough in cardiovascular medicine will likely require a more holistic approach to inflammation. Until then, the search for a drug that can reliably translate lower inflammatory markers into longer lives and fewer hospitalizations continues across the industry.[4][5]